HanIn Sitagliptin Tablets 100 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
HanIn Pharmaceutical Co., Ltd.
MFDS item code 201502347 · Approved 2015.04.17
This product's status changed to Expired on 2025.04.17. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in type 2 diabetes
This medication is used along with diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be used alone but may also be combined with metformin or other diabetes medications to enhance blood sugar management when existing treatments are insufficient. This medication is added to various combination therapies to improve blood sugar control in patients with type 2 diabetes.
This medicine is administered at 100 mg once daily as monotherapy or in combination therapy, and the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Since dosage adjustment based on renal function is required, assessment of renal function before treatment and periodically thereafter is recommended. 1. No dosage adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions, so if symptoms such as rash or difficulty breathing occur, discontinue use immediately and consult a doctor. While taking this medication, inflammation of the pancreas, known as pancreatitis, may occur, so if symptoms like abdominal pain, vomiting, or loss of appetite arise, notify medical personnel promptly. It is advisable not to use this medication in patients with type 1 diabetes or diabetic ketoacidosis. Those who have experienced severe allergic reactions to this medication or its components should avoid taking it. Patients with impaired kidney function should adjust the dose of this medication, so regular kidney function tests before and during treatment are important. In clinical trials, patients taking this medication may experience side effects such as cold symptoms, headaches, and upper respiratory infections. Additionally, hypoglycemic symptoms may occur, so it is crucial to monitor blood sugar levels frequently and pay attention to symptoms, especially when taken with insulin or other sulfonylureas. If severe joint pain or blistering symptoms occur while taking this medication, discontinue use immediately and consult medical personnel. It is not safe for pregnant or nursing women to take this medication, and its safety and efficacy in children or adolescents under 18 years of age have not been established. Elderly patients may experience decreased kidney function, so dose adjustments and kidney function tests are necessary. In the case of overdose, it may be necessary to remove the drug from the gastrointestinal tract and monitor the condition with tests such as an electrocardiogram, and, if required, the drug can be removed through dialysis. Although no significant drug interactions have been reported with this medication when taken with numerous other drugs, caution may be necessary when combined with specific medications, so it is essential to inform medical personnel of other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to prevent air and moisture from entering. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the effectiveness of the medication for a long time.
Beige, round, and biconvex film-coated tablet
30 tablets/bottle, 90 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
HanIn Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.